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CID: Collision Induced Dissociation 
FBS: Fetal Bovine Serum 
IDMS: Isotope Dilution Mass Spectrometry 
IFNJ: interferon J 
MSCs: Mesenchymal Stem Cells 
SILAC: Stable Isotope Labeling by Amino acids in Cell culture 
SRM / MRM: Single Reaction Monitoring / Multiple Reaction Monitoring 
SVF: Stromal vascular fraction 
 
Summary: 
The proteasome controls a multitude of cellular processes through protein degradation and has been 
identified as a therapeutic target in oncology. However, our understanding of its function and the 
development of specific modulators are hampered by the lack of a straightforward method to 
determine the overall proteasome status in biological samples. Here, we present a method to 
determine the absolute quantity and stoichiometry of ubiquitous and tissue-specific human 20S 
proteasome subtypes based on a robust, absolute SILAC-based multiplexed LC-Selected Reaction 
Monitoring (SRM) quantitative mass spectrometry assay with high precision, accuracy, and sensitivity. 
The method was initially optimized and validated by comparison with a reference ELISA assay and by 
analyzing the dynamics of catalytic subunits in HeLa cells following IFNJ-treatment and in range of 
human tissues. It was then successfully applied to reveal IFNJ- and O2-dependent variations of 
proteasome status during primary culture of Adipose-derived-mesenchymal Stromal/Stem Cells 
(ADSCs). The results show the critical importance of controlling the culture conditions during cell 
expansion for future therapeutic use in humans. We hypothesize that a shift from the standard 












proteasome to the immunoproteasome could serve as a predictor of immunosuppressive and 
differentiation capacities of ADSCs and, consequently, that quality control should include proteasomal 
quantification in addition to examining other essential cell parameters. The method presented also 
provides a new powerful tool to conduct more individualized protocols in cancer or inflammatory 
diseases where selective inhibition of the immunoproteasome has been shown to reduce side effects.  
 
Introduction: 
Some hematopoietic malignancies can be successfully treated by inhibition of the catalytic core 20S 
proteasome complex, and more recent findings indicate that the proteasome is a promising target for 
the treatment of other cancer types or other pathologies including inflammatory diseases (1–3).  
Although the cylindrical α7β7β7α7 barrel-like structure of the 20S catalytic core proteasome has been 
preserved throughout evolution, the oligomeric protease has evolved, resulting in a higher 
heterogeneity of subunit compositions in mammals. As schematically represented in Figure 1A, there 
exist at least six distinct forms of 20S proteasomes in human cells and tissues. The standard 20S 
proteasome (sP20S) is composed of constitutive (D1–D7 and β3, β4, β6, and β7) and catalytic subunits 
(β1, β2 and β5). It is the most abundant 20S subcomplex in most cell types, but significant amounts of 
other 20S forms have been observed in some human tissues and cells in their basal state, or are 
induced in specific environmental conditions (4). For instance, in response to pro-inflammatory 
cytokines or in immune cells, the three catalytic subunits of the sP20S can be replaced in a highly-
regulated way by their immuno counterparts to form the immunoproteasome (iP20S), which has non-
identical cleavage specificities (5). Two intermediate proteasomes harboring a mixed assortment of 
standard and immunocatalytic subunits (β1i P20S, β1iβ5i P20S) have also been observed in various 
human tissues and cells, and their existence is consistent with the rules of cooperative assembly of 
inducible catalytic subunits (6). Some other 20S subtypes are much more tissue-specific, such as the 
thymoproteasome (containing β1i, β2i and β5t catalytic subunits) and the spermatoproteasome 












(containing a specific isoform of D4 called D4s) which are found in the thymus and male germ cells, 
respectively. The environment- or tissue-specific subunit composition of human 20S proteasome has 
been shown to fulfill specialized functions that the standard proteasome can only exert suboptimally 
(4). For example, immune cells contain a significant proportion of immunosubunit-containing 20S 
proteasome subtypes which display specific proteolytic preferences thanks to which they produce 
antigens for presentation to CD8 T cells (6). In the thymus, the unique cleavage preference of β5t 
explains the essential role played by the thymoproteasome in the positive selection of developing T 
lymphocytes (7). Thus, knowledge of 20S proteasome composition will help us to better understand 
proteasome function in a given tissue or cell type. It is also crucial when developing novel therapeutic 
strategies targeting specific 20S proteasome variants. Indeed, the immunoproteasome is a valuable 
target in several ongoing oncology trials as well as in the treatment of inflammatory and autoimmune 
diseases (2, 3, 8). To assess proteasome status, by determining the absolute quantity and stoichiometry 
of all subtypes, thus requires precise and accurate absolute quantification of several subunits from the 
same biological sample. As mRNA and protein levels reported from proteomic and transcriptomic 
analyses show a low correlation (9), quantification must be performed at the protein level to allow an 
accurate and complete description of the 20S proteasome status. Several ELISA protocols have been 
published or are commercially available to determine absolute levels of both 20S and 26S proteasome 
complexes, but only at the global level, i.e., they make no distinction between the different 
subcomplexes (6, 10–14). Only Guillaume et al. (6) considered the heterogeneity of 20S subtypes when 
developing their ELISA assay by using different in-house produced antibodies directed against four 
different standard and immunocatalytic β subunits. More recently, standard and immunoproteasome 
subtypes were determined by surface plasmon resonance imaging (SPRI) using specific inhibitors (15). 
However, the multiplexing capacity of these methods is insufficient to fully assess proteasome 
heterogeneity in a single assay. 
To overcome this limitation, we propose to use Selected Reaction Monitoring (SRM), an isotope 
dilution mass spectrometry (IDMS)-based technique which has been approved for the quantification 












of multiple biomolecules. In addition to its robustness, precision and accuracy, the main advantage of 
SRM is its capacity to quantify many analytes simultaneously. SRM has recently been successfully 
applied in protein assays (16, 17). In these studies, the proteins themselves were not directly detected 
and quantified, but were analyzed at peptide level, after enzymatic proteolysis. This is a critical step 
because, in most cases, the absolute quantification relies on the addition of an isotopically-labeled 
peptide standard (called AQUA peptide) (18) late in the experimental workflow, which might introduce 
a high variability due to differences in sample preparation. Thus, for accurate and robust absolute 
quantification of proteins, and in particular to determine protein stoichiometry within protein 
complexes, the use of isotope-labeled peptides as internal standards requires careful optimization of 
experimental conditions (19). An alternative approach based on artificial genes coding for 
concatenated proteotypic peptides (QconCAT strategy) (20) may be used to decrease quantification 
biases. For robust absolute quantification, an isotope-labeled equivalent of the full-length target 
protein is considered the ideal internal standard. Several approaches based on the synthesis of heavy 
versions of the protein of interest have emerged recently. Most of them rely on metabolic labeling and 
purification of a recombinant version of the protein of interest, or a shorter specific protein sequence, 
like the Protein Standards for Absolute Quantification (PSAQ) (21), absolute SILAC (22), PrEST (23), 
FlexiQuant (24), and TAQSI (25) methods. Another approach consisting in the chemical labeling of 
proteins using isobaric stable isotope tagging technology (26) has recently been described to reduce 
costs and the time required to grow cells in heavy amino acid-containing media. In all these 
approaches, because the internal standard is processed together with its endogeneous analog 
throughout the whole workflow, accuracy is markedly better than achievable with AQUA and QconCAT 
approaches when determining absolute quantities of proteins in various matrices (17). However, to 
our knowledge, the absolute quantification relying on the isotopic dilution of labeled proteins has been 
limited so far to monomers, and no reports of assays to determine the stoichiometry of 
macromolecular complexes have been published.  












Mesenchymal stem/stromal cells (MSC) hold great potential in regenerative medicine because of their 
multi/pluripotency and immunosuppressive properties. Over the last decade, the clinical use of MSC 
has rapidly increased, and more than 800 clinical trials assessing MSC therapy in multiple clinical 
settings are currently registered (https://www.clinicaltrials.gov/). Adipose-derived Stem Cells (ADSCs) 
are a subclass of mesenchymal stem/ stromal cells initially derived from the bone marrow. However, 
to obtain the critical number of cells before transplantation, ADSCs must be expanded in vitro. This 
essential step has raised important concerns about the quality of adult stem cells, and inter-patient 
variability is a challenge when seeking to define ADSCs. The development of uniform protocols for both 
preparation and characterization of MSCs, including standardized functional assays to assess their 
biological potential, will be critical in contributing to their clinical utility. 
Here, we applied the SILAC method to engineered cell lines expressing either the standard 20S 
proteasome or the immunoproteasome to produce and purify isotope-labeled, endogeneous versions 
of standard proteasome and immunoproteasome in vivo. These isotope-labeled proteasome 
complexes were used as internal standards to quantify the absolute concentration of all 20S catalytic 
and non-catalytic subunits in biological samples of various origins. The method developed was applied 
to determine the absolute concentration of total 20S proteasomes and the exact stoichiometry of six 
ubiquitous and tissue-specific 20S proteasome subtypes in a multiplexed LC-SRM assay with high 
precision (>92%), accuracy (>90%), and sensitivity (<1 fmol on column). Our results show that the 
absolute quantity and stoichiometry of the proteasome are challenged both by IFNγ stimulation and 
O2 levels during ex vivo expansion of primary ADSCs. Thus, determining proteasome status, which is a 
central contributor to maintaining stem cell homeostasis – characterized by stemness, capacity for 
self-renewal and cell differentiation (27–29) – might constitute an additional relevant quality control 
parameter for the production of ADSCs for clinical applications, which is of interest as the number of 
quality markers currently available is limited (30). Furthermore, accurate and precise assessment of 
proteasome abundance and heterogeneity could also help when seeking to achieve selective inhibition 
of a particular proteasome subtype, like the immunoproteasome, for personalized therapies in cancer 












or autoimmune diseases. This is the first study to report the simultaneous determination of absolute 
quantity and stoichiometry for macromolecular complexes based on the isotopic dilution of labeled 
proteins in numerous human tissues and primary ADSCs culture.  
  
Experimental Procedures 
Cell lines, Culture conditions, SILAC, human samples 
HEK 293T, HCT116, HeLa and RKO cell lines were grown in DMEM medium supplemented with 10% 
fetal bovine serum (FBS). U937, HeLa S3 and NB4 cell lines were grown in RPMI 1640 medium 
supplemented with 10% FBS. KG1a cell line was grown in RPMI 1640 medium supplemented with 20% 
FBS. MRC5 cell line was grown in MEM-α medium supplemented with 10% FBS. All cultures were 
supplemented with 2×10−3 M glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, and 
maintained at 37 °C under 5% CO2. Unsynchronized cells were harvested at 80% confluence for 
adherent cells or at a concentration of 1.106 cells per ml of culture for suspension cells. HeLa cells were 
treated with interferon-γ (R&D Systems, Minneapolis, MN) at 100 ng/ml in fresh medium. 
Human 293-EBNA cells, “HEK-EBNA sP20S” (mainly expressing sP20S), and 293-EBNA cells engineered 
to express iP20S, “HEK-EBNA iP20S” (by transfecting 293-EBNA cells with cDNAs encoding the three 
immunocatalytic subunits β5i, β1i and β2i) were obtained as previously described (6). HEK-EBNA sP20S 
cells were cultured in SILAC medium which is composed of DMEM supplemented with 10% dialyzed 
FBS, 4 mM L-glutamine, 200 mg/L L-Proline, 100 mg/mL L-arginine (13C6), and L-lysine (13C6) (Cambridge 
Isotope Lab.), 100 IU/mL penicillin and 100 μg/mL streptomycin in 150 cm² culture plates and 
maintained at 37°C under 5% CO2. HEK-EBNA iP20S were cultured in the same SILAC medium as HEK-
EBNA sP20S, but further supplemented with 5 μg/mL Puromycin and 600 μg/mL Hygromycin to 
maintain selective pressure. Ten cellular doublings were performed in this medium to achieve an 
incorporation rate of 95% heavy amino acids in proteins (assessed by MS). Standard 20S proteasome 
and iP20S were then purified as described earlier (31). Absolute quantities and purities of both purified 












proteasome subtypes were then assessed as described in Supplementary information I-1. Isotope-
labeled sP20S and iP20S were stored as 10-μL aliquots at 1.158 and 0.980 pmol/μL, respectively, in 
20 mM Tris/HCl, pH 7.2, 1 mM EDTA, 1 mM DTT, 10% glycerol, and at -80°C to ensure stability over 
time. 
Whole-cell lysates from various human tissues were supplied by AMSBio (HT-201 (Brain); HT-311 
(Colon); HT-804 (Heart); HT-314 (Liver); HT-601 (Lung); HT-406 (Ovary); HT-102 (Skeletal muscles); HT-
701 (Spleen); HT-401 (Testis); HT-704 (Bone Marrow); P1234264 (Thymus)). 
Human ADSC were isolated from subcutaneous adipose tissue (AT) obtained from non-obese human 
donors (body mass index <26) undergoing elective abdominal dermolipectomy (Plastic Surgery 
Department, Rangueil Hospital, Toulouse, France). No-objection certificates were obtained to comply 
with bioethics law no. 2004-800 of 6 August 2004. The stromal vascular fraction (SVF) was obtained by 
enzymatic digestion of adipose tissue (AT) with collagenase NB4 (Roche Diagnostics, Indianapolis, IN). 
Cells were then seeded at 4,000 cell/cm2 (P0) and cultivated in α-minimal essential medium 
supplemented with 10% FBS (Gibco), 100 μg/ml streptomycin, 100 U/ml penicillin, 25 μg/ml 
amphotericin (Thermo Fisher Scientific Life Sciences, Waltham, MA). Medium was changed twice a 
week. Cells from the same patients were cultured under normoxic (20% O2, 5% CO2) or hypoxic (1% or 
5% O2, 5% CO2) conditions in an Xvivo System (BioSpherix, Paris, NY) to maintain cells in hypoxic 
conditions at all culture steps. Interferon-J (100 ng/ml) was added to the medium in some 
experiments. 
Our experimental protocols were approved by French research ministry’s institutional ethics 
committee of (N°: DC-2015-23-49) and informed consent was obtained from all subjects in line with 
current regulations (no subjects age under 18 were included). 
 
Adipocyte differentiation  












ADSCs obtained from patients were seeded at 20,000 cell/cm2 and were exposed to an adipogenic 
cocktail containing IBMX (3-isobutyl-1-methylxanthine) 0.45 mM, Dexamethazone 1 PM and 
Indomethacine 60 PM. An immunoproteasome inhibitor, 100 nM ONX-0914 (solubilized in 0.001% 
DMSO), was also added to the cell medium in some conditions; 0.001% DMSO was added to the control 
condition in these cases. Cells were grown at 37 °C under normoxic (20% O2) or hypoxic conditions 
(5% and or 1% O2). The medium was changed every 2–3 days throughout the culture process. At 
the end of experiment, the cell lineage was determined using Oil Red O which stains for adipocytes. 
 
20S Proteasome purification.  
When they reached 80% confluence, HEK-EBNA cell lines (HEK-EBNA sP20S or HEK-EBNA iP20S) were 
harvested in HKMG buffer (10 mM Hepes pH 7.9, 10 mM KCl, 5 mM MgCl2, 10% glycerol, 10 mM ATP, 
1% NP40, protease and phosphatase inhibitor (Roche)) and centrifuged for 10 min at 10,000 g. 
Supernatants were kept and used for proteasome immuno-purification as previously described (31). 
 
ELISA-based absolute quantification of the 20S proteasome  
ELISA-based absolute quantification of the 20S proteasome was performed as previously described 
(14). Briefly, ELISA assays were performed in 96-well plates (IMMULON HBX 4, Thermo Scientific, 
Milford, MA, USA). The plate was coated with 100 μL MCP21 monoclonal antibody (European 
Collection of Cell Cultures) at 5 μg/mL by incubation at 4 °C overnight. Wells were then washed 3 times 
with PBS/T-buffer. Non-specific sites were blocked by incubation with 2% BSA in PBS for 1 h at room 
temperature with slow shaking. The plate was washed 3 times with PBS/T-buffer. The samples (cell 
lysates) were then deposited in triplicate and incubated for 2 h at room temperature. The plate was 
washed with PBS/T-buffer and then incubated with the polyclonal rabbit anti-20S antibody (PW 8155, 
ENZO LIFE Sciences) for 1 h at room temperature under slow shaking. The plate was washed 3 times 












with PBS/T-buffer and antibody binding was revealed using horseradish peroxidase-conjugated anti-
rabbit antibody and 2 mg/mL ABTS substrate (2,2-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)). 
The reaction was monitored by measuring the optical density at 416 nm (μQuant; Bio-Tek instruments, 
Inc., Winooski, VT, USA). The amount of proteasome in the sample was calculated by comparison with 
the calibration curve produced with purified 20S proteasome purified from human erythrocytes (ENZO 
LIFE SCIENCE). A linear dose–response was observed between 0 and 20 ng. 
 
Proteasome activity assay  
Cultured cells were harvested in HKMG buffer and sonicated in ice with a Bioruptor Plus (Diagenode) 
(15 min, cycle 45 s/15 s (ON/OFF), position High). Protein concentration was determined by detergent-
compatible protein assay (DC Assay – BioRad) according to the manufacturer’s recommendation. 
Proteasome activity was assayed in 96-well black plates (Greiner Bio-One, Frickenhausen, Germany). 
10 μL of each lysate fraction were added to 40 μL of Tris-HCl 100 mM and 50 μL of Suc-LLVY-AMC (for 
chymotrypsin-like activity), Boc-LRR-AMC (for trypsin-like activity) and Z-LLE-AMC (for PGPH activity) 
substrate in 200 mM Tris-HCl, pH 8 (Enzo Life Science) at a final concentration of 400 μM/well. Kinetic 
assays were performed at 37 °C in a FLX-800 spectrofluorometer (BIOTEK, Winooski, VT, USA) over 
90 min, reading fluorescence every 5 min, at 460 nm following excitation at 360 nm. 












Samples preparation and in-gel digestion for mass spectrometry analysis 
Samples were heated to 95 °C for 5 min in Laemmli buffer to denature proteins; 100 mM 
chloroacetamide was then added to the sample followed by incubation for 30 min at room 
temperature in the dark. Proteins were loaded onto a 12% acrylamide SDS-PAGE and concentrated in 
a single band, visualized by Coomassie staining (Instant Blue – Expedeon). The gel band containing the 
whole sample was cut and washed several times in 50 mM ammonium bicarbonate, acetonitrile (1:1) 
for 15 min at 37 °C. Trypsin (Promega) digestion was performed over night at 37 °C in 50 mM 
ammonium bicarbonate at a trypsin/total protein ratio of 1/50. Peptides were extracted from the gel 
by two incubations in 10% formic acid, acetonitrile (1:1) for 15 min at 37 °C. Extracts were dried in a 
Speed-Vac, and resuspended in 2% acetonitrile, 0.05% trifluoroacetic acid prior to LC-MS/MS analysis. 
For LC-SRM analysis, 1 pmol of labeled iP20S and 1 pmol of labeled sP20S were added to 25 μg of total 
proteins before the protein denaturation step. When used, AQUA peptides (Thermo Scientific Pierce 
Protein Research) were spiked into samples just before mass spectrometry analysis at a concentration 
resulting in injection of a final quantity of 70 fmol. 
 












Whole proteome analysis of extracts from human tissues and ADSCs grown under normoxic and in 
hypoxic conditions (1% O2). Peptide mixtures were analyzed by nano-LC-MS/MS using an 
Ultimate3000 system (Dionex) coupled to an LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher 
Scientific, Bremen, Germany) when analyzing human tissue extracts or to a Q-Exactive Plus mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany) when analyzing ADSCs. Five microliters 
(human tissue) or two microliters (ADSCs) of each peptide sample at 1 μg/μL were loaded onto a C18 
precolumn (300 μm inner diameter x 5 mm; Thermo Scientific) at 20 μL/min in 5% acetonitrile, 0.05% 
trifluoroacetic acid. After 5 min of desalting, the precolumn was switched online with the analytical 
C18 column (75 μm inner diameter x 50 cm; home-made) equilibrated in 95% solvent A (5% 
acetonitrile, 0.2% formic acid) and 5% solvent B (80% acetonitrile, 0.2% formic acid). Peptides from 
human tissues were eluted using a 5–50% gradient of solvent B over 105 min at a flow-rate of 
300 nL/min and peptides from ADSCs were eluted using a 5–25% gradient of solvent B over 165 min 
and a 25-50% gradient of solvent B over 135 min at a 300 nl/min flow rate. Both mass spectrometers 
were operated in data-dependent acquisition mode. During the analysis with the LTQ-Orbitrap Velos, 
survey scan MS spectra were acquired in the Orbitrap over the 350–1800 m/z range with resolution 
set to 60,000 (these parameters were 350-1500 m/z and 70,000 with Q-Exactive Plus, respectively).  
On the LTQ-Orbitrap Velos, the twenty most intense ions per survey scan were selected for CID 
fragmentation, and the resulting fragments were analyzed in the linear trap (LTQ). On the Q-Exactive 
Plus, the ten most intense ions per survey scan were selected for HCD fragmentation, and the resulting 
fragments were analyzed in the Orbitrap. Dynamic exclusion was used with a 60-s or a 30-s window 
(on the LTQ-Orbitrap Velos or the Q-Exactive Plus, respectively) to prevent repeated selection of 
peptides.  
Raw mass spectrometry files were processed using MaxQuant (version 1.5.5.1) and Andromeda was 
used to match MS/MS spectra against the Human SwissProt database (March 2017 release – 20,181 
entries for human tissues analysis / release of August 2018 – 20,386 entries for ADSCs analysis) and a 
list of potential contaminant sequences provided in MaxQuant1.5.5.1., with Carbamidomethylation of 












cysteines set as fixed modification. Oxidation of methionine and protein N-terminal acetylation were 
set as variable modifications. The digestion specificity of trypsin was defined as cleavage after K or R, 
and up to two missed trypsin cleavage sites were allowed. The precursor mass tolerance was set to 
20 ppm for the first search and 4.5 ppm for the main search. The mass tolerance in MS/MS mode was 
set to 0.8 Da for tissue analysis and to 20ppm for ADSC analysis. Minimum peptide length was set to 
seven amino acids, and minimum number of unique peptides was set to 1. A target-decoy approach 
was used to validate hits, using a reverse database and applying a peptide and protein false-discovery 
rate of 1%. The “match between runs” option in MaxQuant was enabled, with a time window of 
0.7 min, to allow cross-assignment of MS features detected in different runs. Only unique peptides 
were used for quantification when analyzing human tissues, whereas both unique and razor peptides 
were used for the quantification when dealing with ADSCs data. Quantitative proteomic analysis was 
performed on the normalized LFQ intensities from the “proteinGroups” table in the MaxQuant output. 
Protein entries identified as potential contaminants by MaxQuant were eliminated from the analysis, 
as were proteins identified by fewer than two peptides. Tissue-specific 20S proteasome subunits (α4s, 
β1i, β2i, β5i, and β5t) were compared across the different tissues based on their normalized LFQ 
intensities (Figure 3B). To compare the proteomes of ADSCs grown under normoxic or hypoxic 
conditions, the LFQ intensity values were used for the quantitative analysis. Fold-changes were log2 
transformed and thresholds calculated based on their distribution. The upper threshold was calculated 
as Q3 + 1.5*IQ, and the lower threshold as Q1 - 1.5*IQ, where IQ is the interquartile, and Q1 and Q3 
are the first quartile and the third quartile, respectively. Proteins with fold-changes outside these 
thresholds were considered outliers from the global distribution. Outlier proteins with a p-value of less 
than 0.05 were considered as differentially expressed between normoxic and hypoxic conditions. GO 
terms enrichment analysis was performed on these proteins using GOrilla (32). 
 












Multiple Reaction Monitoring to quantify 20S proteasome subunits 
Dried peptide samples were resuspended in a solution containing 2% acetonitrile, 0.05% TFA, to obtain 
a final concentration of 1 μg/μL. To obtain data for the whole set of peptides/transitions, samples were 
injected twice as the list of transitions was split into two methods. The sample (2.5 μL, about 2.5 μg 
protein equivalent) was loaded onto the system and analyzed on a hybrid triple quadrupole-ion trap 
mass spectrometer 6500 QTrap (AB Sciex) equipped with a nanoelectrospray ion source coupled to an 
Ultimate 3000 system (Dionex) for chromatographic peptide separation. Separation was achieved 
using a 60 min gradient from 0 to 50% of solvent B (80% acetonitrile, 0.2% formic acid) at a flow-rate 
of 300 nL/min. Spray voltage was set to 2500 V, curtain gas to 35 psi, nebulizer gas to 5 psi, interface 
heater temperature to 75 °C, and cycle time to approximately 3 s (3.1620 s and 3.0380 s for the two 
methods). Peptides were loaded onto a C18 precolumn (300 μm inner diameter x 5 mm; Thermo 
Scientific) at 20 μL/min in 2% acetonitrile, 0.05% trifluoroacetic acid. After 5 min of desalting, the 
precolumn was switched online with the analytical C-18 column (75 μm inner diameter x 50 cm; in-
house-packed with Reprosil C18) and equilibrated in solvent A (5% acetonitrile, 0.2% formic acid).  
Proteotypic peptide sequences were selected based on results of previous discovery experiments (33–
35) and by referring to the golden rules (16) (i.e., considering isoforms, variants, PTMs reported on 
protein sequence or possibly artefactually-induced by sample handling, or missed cleavages, observed 
in Protein (UniProt) or MS databases (PeptideAtlas)). To achieve maximal sensitivity, collision energies 
(CEs) were optimized within a 6 V window around the CE value recommended by Skyline software and 
based on the m/z of the precursor. Final SRM transitions are given in Supplementary Data 3. Transitions 
could be unambiguously assigned thanks to the co-injected isotope-labeled peptides. Samples were 
run in a blinded fashion except for calibration curves, for which the lowest concentrations were 
injected first. To check system suitability and performance before injecting each batch of samples, 
Total Ion Current was tuned (chromatographic solvent ions of m/z 50 to 1000) at 2000 Da/s scan speed 
in Q1. Quality controls (QC) (20 fmol of tryptic digest of betagalactosidase; transitions are given in 












Supplementary Data 4) were injected between each sample. Carry-over was checked by injecting 
tryptic digests of 100 fmol, 500 fmol or 1000 fmol of isotopically-labeled sP20S and iP20S spiked in 
2.5 μg of HeLa, then one QC sample, and finally a blank sample (the maximum carry-over observed 
was less than 0.01%). Quantitative reproducibility over time was checked based on signal intensities 
for heavy transitions (maximum deviation of 50% allowed); injection batches were generally carried 
out over periods of less than one week. 
Quantitative data analyses were performed using Skyline-Daily open-source software (36). Area values 
for all transitions were first extracted automatically by the software, then checked manually and 
adjusted if necessary (i.e., exclusion of data points if S/N < 10). Light transition (L) peak area signals 
were then normalized with respect to their labeled counterparts (H) (after correction by considering 
the 95% incorporation rate for R(13C6) and K(13C6) in labeled sP20S and iP20S). For each transition, 
technical replicates of injection (typically three) were averaged. Ratios (L/H) of all the transitions used 
to assay a given protein or for total 20S proteasome (details in Supplementary Data 3) were then 
averaged. The amount of labeled reference mix (containing equimolar concentrations of isotope-
labeled sP20S and iP20S) spiked into the biological sample before sample preparation was then used 
to determine the absolute quantity of each proteasome subunit or total 20S proteasome. For each 
transition, LOD and LLOQ were experimentally determined by injecting heavy-isotope-labeled sP20S 
and iP20S spiked at increasing concentrations in a HeLa protein lysate and processed by the same 
method as applied to the other biological samples. LOD and LLOQ values were calculated using QuaSAR 
(37), which was implemented through the Skyline interface (see Supplementary Data 5). 
Targeted MS measurements were highly multiplexed, and used to quantify proteasome subunits 
across cell lysates, tissues and primary cells of human origin. The assay developed used internal 
standards for each analyte, to confidently detect and precisely quantify the proteins of interest. Thus, 
the analyses meet the expectations of Tier 2 level. 












Determining the stoichiometry of the six major 20S proteasome subtypes 
The concentrations and stoichiometries of all proteasome subtypes were determined as explained 
hereafter.  
Total proteasome absolute quantity was calculated by averaging the quantities of all 20S non-catalytic 
subunits (α1-7; β3, β4, β6, β7) (mean (α1,2,3,5,6,7; β3,4,6,7) Î Total P20S). A stoichiometry of two 
non-catalytic subunits per 20S proteasome and a molecular weight of 700,000 g/mol were used in 
these calculations. 
As β5 is integrated into the standard proteasome, its fraction exclusively represents the fraction of 
standard proteasome (β5 Î sP20S). Similarly, the level of β5t corresponds to the fraction of 
thymoproteasome “β5t P20S”, and can be obtained by subtracting the sum of β5 and β5i levels from 
the total amount of 20S proteasome (Total P20S - β5 - β5i = β5tÎ β5t P20S). As the β2i subunit is 
integrated into both the immunoproteasome and the thymoproteasome, the difference in its quantity 
compared to β5t can be used to determine the fraction of immunoproteasome (β2i – β5t Î iP20S). 
The β1i-containing proteasome subtypes correspond to immunoproteasome, thymoproteasome, and 
intermediate proteasome β1i- β5i. Thus, the quantity of β1i- β5i P20S is equal to the difference in 
abundance of β1i and β2i proteins since both immunoproteasome and thymoproteasome contain β2i 
(β1i – β2i Î β1iβ5i P20S). ß5i is contained in the immunoproteasome and in both types of 
intermediate proteasomes (β5i Î iP20S + β5i P20S + β1iβ5i P20S). Thus, the amount of β5i P20S can 
be calculated as follows: β5i + β5t – β1i = Total P20S – β1i – β5 Î β5i P20S. 
 Finally, the spermatoproteasome level can be determined from the quantity of the α4s isoform (PSA7L 
protein _PSMA8 gene) by subtracting the abundance of the α4 subunit from the total 20S proteasome 
content (using specific peptides of the PSA7 isoform_PSMA7 gene as detailed in Sup Figure 8A) (sP20S 
– α4 Î α4s P20S).  












Thus, the absolute amounts of non-catalytic subunits, as well as those of the catalytic β2i, β5, β5i and 
ß1i subunits determined by the SRM method were used to calculate the proportions of the six main 
20S proteasome subtypes, as summarized below: 
mean (α1,2,3,5,6,7; β3,4,6,7) Î Total P20S  
β5 Î sP20S 
Total P20S - β5 - β5i = β5tÎ β5t P20S  
β2i – β5t Î iP20S 
β1i – β2i Î β1iβ5i P20S  
P20S – β1i – β5 Î β5i P20S  
sP20S – α4 Î α4s P20S  
 
Experimental design and statistical rationale 
SRM analyses: All statistical analyses were performed on at least three independent biological 
replicates. For each biological replicate, results from at least two injection replicates were averaged. 
Probability values (p) were determined by one-way and two-tailed analysis of variances (ANOVA). 
Differences were considered to be statistically significant at confidence levels of 95% (*), 99% (**), or 
99.9% (***). 
Coefficients of variation were calculated as ratios of the standard deviation over the mean of the values 
and are expressed as a percentage. Accuracy was determined as the ratio of the difference of the 
experimental value and the reference value over the reference value, and is expressed as a percentage.  
Label-free MS analyses (Figure 3B and Supplementary Figure 11): The “human tissue extract” dataset 
contains mass spectrometry results from the analysis of 11 different human tissues analyzed in 












triplicate, corresponding to 33 raw files. The “ADSC” dataset contains mass spectrometry results from 
the analysis of three different patients under two different oxygen percentages used for cell culture, 
samples were analyzed in triplicates, and thus produced 18 raw files. Quantitative proteomic analysis 
was performed on the normalized LFQ intensities from the “proteinGroups” table in the MaxQuant 
output.  
The data sets corresponding to the mass spectrometry analyses presented in this study have been 
deposited in the following repositories:  PRIDE (Project accession: PXD011894) for label-free MS 
analyses, and PeptideAtlas (Dataset identifier: PASS01219) for targeted MS analyses. The detailed 
descriptions of all analyses (raw and processed file names, sample name, biological replicate number, 
MS technical replicate number, corresponding figure) are summarized in Supplementary Data 8. 
 
Results 
Design and validation of the SRM assay to determine 20S proteasome status  
The method aimed to simultaneously determine the absolute 20S proteasome quantity and subtype 
stoichiometry in a single assay. To achieve this goal, we designed a workflow combining IDMS and SRM 
to exploit its multiplexing capacity, sensitivity and robustness. In terms of total 20S proteasome 
absolute quantification, preliminary optimizations were used to select the most appropriate mode of 
internal standardization to correct for a range of experimental biases (Figure 1B; Supplementary 
Information I-1). As detailed in Supplementary Information I-1 and Supplementary Figures 1-5, the 
isotope-labeled whole proteasome complex added to biological preparations clearly provide a much 
more robust absolute quantification method than spiking with individual isotope-labeled “AQUA” 
proteotypic peptides for each 20S subunit. Indeed, despite good analytical performance in terms of 
reproducibility and linearity, absolute quantification using AQUA peptides technology lacked accuracy. 
This critical issue was overcome by using the absolute SILAC quantification method. We produced and 
affinity-purified isotope-labeled standard proteasome and immunoproteasome to obtain highly pure 












standards with a high level of subtype purity (min 99%) and with an excellent isotopic incorporation 
rate (min 95%) (Supplementary Information I-1, Sup Figures 3 & 4). The optimized quantification 
method then consisted in the distribution of a reference mixture of 20S proteasome subunits with 
carefully-controlled stoichiometry into protein lysates (Figure 1B). After digestion of proteins using 
trypsin, an SRM method including at least one peptide sequence (with three associated transitions for 
each light and labeled surrogate) for the 11 non-catalytic subunits (α1-7; β3, β4, β6, β7) 
(Supplementary Data 3) was applied. With this method, absolute quantification of total 20S 
proteasome was achieved in protein lysates of eight different human cell lines of diverse origins (HEK 
293T, HCT116, RKO, U937, HeLa S3, NB4, KG1a, and MRC5). 20S proteasome concentration determined 
by the SRM method was compared to those obtained with the reference ELISA method (Figure 2A). A 
high correlation was found between the two methods (coefficient of determination = 0.98; slope = 
1.01). Altogether, these data demonstrate that the newly-developed method is suitable for absolute 
quantification of 20S proteasome in human cell lysates. 
Next, we implemented the method to detect the six standard and immune-specific catalytic subunits 
of the 20S proteasome (β1, β2, β5, β1i, β2i, β5i), as the absolute quantification of these subunits is 
required to determine the stoichiometry of the different 20S proteasome subtypes present in 
biological samples (Figure 1). Two to three proteotypic peptide sequences (and three or four 
associated transitions for each light and labeled surrogate) were carefully chosen, paying attention to 
favoring wide distribution over the protein sequence. Transitions and detection were then optimized 
for the six catalytic subunits. In total, the final method to quantify all α and β subunits comprised 206 
independent MS transitions (103 “light” transitions and 103 “heavy” transitions corresponding to 
heavy surrogate peptides) associated with optimized dwell times and voltages for detection by the 
mass spectrometer (Supplementary Data 3). The method to quantify of the absolute levels of all six 
20S proteasome catalytic subunits was validated by taking advantage of the known stoichiometry of 
incorporation of catalytic subunits into the 20S proteasome (Supplementary Information I-2). Based 
on the excellent accuracy (97 ± 2%) and variability (CVs below 15%) of the method to measure the 












absolute levels of catalytic subunits (Supplementary Information I-2 and Supplementary Figure 7B&D), 
these data were further used to determine changes in the stoichiometries of the four 20S proteasome 
subtypes observed in a model of IFNJ-treated HeLa cells (sP20S, β5i P20S, β1iβ5i P20S, and iP20S – no 
β5t P20S nor α4s P20S detected) (as detailed in Experimental Procedures) (Figure 2B). As expected, 
iP20S was highly and significantly increased (by a factor of 12), becoming the major proteasome 
subtype after 96 h stimulation with IFNJ, whereas sP20S levels dropped by nearly 3-fold (Figure 2B). 
Strikingly, the two intermediate 20S immunoproteasome subtypes, β5i P20S and β1iβ5i P20S, which 
each represented around 10% of the total 20S present, did not vary significantly after the cytokine 
stimulation. This interesting result shows that the main impact of IFNJ stimulation on the composition 
of proteasome complexes is the progressive replacement of the sP20S by the iP20S subtype.  
 
Determining the stoichiometry of 20S subtypes in human tissues of broad origins 
Next, we applied the method to determine the absolute quantities and precise stoichiometries of 20S 
proteasome subtypes in 11 protein lysates extracted from human tissues of broad origins (Figure 3). 
In most tissues, the proteasome represented 0.2 to 1% of the total protein present (Figure 3A). A 
shotgun label-free LC-MS/MS proteomics analysis exclusively identified and quantified α4s and β5t in 
testes and thymus samples, respectively, confirming their tissue-specificity (4), whereas the 
immunocatalytic subunits (β5i, β1i, and β2i) were much more widely distributed across tissues (Figure 
3B). The stoichiometries of the six major 20S proteasome subtypes (Figure 1A) were determined based 
on the absolute quantities of α and β subunits measured using the optimized method (as explained in 
Experimental Procedures). The absolute level of the catalytic β5t subunit provided the abundance of 
the thymoproteasome (Figure 1A). Because this protein is not incorporated into labeled sP20S and 
iP20S internal standards, the absolute quantity of β5t was deduced from absolute amounts of total 
P20S, β5 and β5i (Figure 3C). Similarly, the α4s subunit (PSMA7L protein) which is representative of 
the spermatoproteasome could not be directly quantified. Although α4 and α4s are very similar in 












sequence, three peptide sequences that are specific to the PSMA7 protein (α4) were detectable and 
were used to distinguish between the two isoforms (Supplementary Figure 8A). The absolute level of 
α4s was deduced from standard P20S and α4 contents (Figure 1B, Experimental Procedures). As in the 
shotgun assay, proteotypic peptides corresponding to the thymoproteasome and 
spermatoproteasome were only observed in thymus and testes tissues, respectively, (Figure 3B) and 
these two 20S proteasome subtypes represented only 20% and 12% of the total proteasome pool in 
these organs, respectively (Figure 3C). A principal component analysis (PCA) biplot based on catalytic 
subunit composition (Figure 3D) grouped brain, muscle, heart, and testes tissues as they almost 
exclusively contain standard proteasome β subunits (β1, β2, and β5). Bone marrow, spleen, and 
thymus, were observed on the opposite side of the graph because they contain high levels of β1i, β2i, 
and β5i immunosubunits. Interestingly, intermediate 20S subtypes (β5i P20S and β1iβ5i P20S) were 
only detected in low abundance (less than 10% of the total 20S proteasome pool) in bone marrow and 
spleen, suggesting that the immunoproteasome is the most important proteasome subtype for antigen 
processing among immunosubunit-containing subtypes. Liver, colon, ovary and lung tissues were 
placed at an intermediary position on the PCA graph (Figure 3D), with 50 to 70% of immunosubunit-
containing 20S proteasome subtypes (Figure 3C).  
Interestingly, the absolute amount of the α4 subunit, measured using peptides common to PSMA7 and 
PSMA7L proteins (Sup Figure 8A-B), was stoichiometric and highly correlated with the total 20S 
proteasome amount (measured using the α and β non-catalytic subunits, apart from α4) both in the 
panel of eight cell lines (R2 = 0.97; slope = 0.99) and in tissues of diverse origins (R2 = 1.00; slope = 1.01) 
(Sup Figure 8 C-D). This result once again confirms the accuracy and precision of the method developed 
while also emphasizing the need for absolute quantification to detect perturbations in proteasome 
subunit expression or incorporation of subunits into mature proteasomes. It also indicates that this 
broad panel of normal and tumor human cells do not contain the non-canonical alternative α4-α4 20S 
proteasome complex in which a second copy of α4 occupies the position normally held by α3 (38, 39).  












The abundance of some proteasome subunits measured using our optimized MRM assay was 
compared with mRNA expression data retrieved from the human protein atlas database (40) in 
corresponding tissues (Supplementary Figure 9). Although positive correlations were observed 
between some proteins and mRNA molecules abundances, these results suggest that measuring mRNA 
levels are not suitable when seeking to predict protein expression levels for 20S proteasome subunits 
in human tissues. 
 
Proteasome status is affected by priming ADSCs with IFNJ during their ex-vivo expansion  
Thanks to their immunosuppressive properties, MSCs are considered a promising tool for cell therapy. 
Much effort has been directed toward enhancing MSCs activity by treatment with IFNJ. However, any 
ex vivo modifications may also fundamentally alter the cells, and understanding determinants that 
affect their immunomodulatory activity is essential if we are to develop effective MSC strategies. MSCs 
obtained from patients must be expanded ex vivo if they are to be used in the clinic, and this process 
must be carefully controlled (41). Recently, we reported a decrease in the immunosuppressive 
properties of ADSCs cultured up to the senescent stage and demonstrated that this effect was the 
result of proteasome-mediated indoleamine 2,3 dioxygenase (IDO) degradation (42). Priming of MSCs 
with IFNJ has been shown to extensively potentiate their therapeutic activity (43, 44) but, to our 
knowledge, and although proteasome functions cover a broad spectrum of biological functions, the 
proteasome status has never been assessed in this context. When used to measure the consequences 
of IFNJ-stimulation of ex vivo-expanded patient-derived ADSCs on proteasome status (Figure 4A), our 
method revealed no major changes in the total 20S proteasome quantity (Figure 4B). However, a 
massive replacement of standard catalytic subunits by their immunological counterparts was clearly 
observed (Figure 4C), resulting in a strong shift from the standard to the immunoproteasome subtype 
(Figure 4D). Indeed, while the standard subtype represented 75% of the 20S proteasome pool when 
ADSCs were expanded in an IFNJ-free medium, this proportion was decreased to 25% after four days’ 












culture in the presence of the cytokine (Figure 4D). The massive induction of the immunoproteasome 
by cytokine stimulation is likely to have a considerable impact on the repertoire of degraded proteins 
and antigenic peptides loaded onto major histocompatibility complex class I (MHCI) molecules. 
  
Expansion of ADSCs under different O2 concentrations affects 20S proteasome status and their 
capacity to differentiate 
Conventionally, MSC culture for clinical applications is performed under normoxic conditions (21% 
oxygen tension), even though oxygen levels within tissues are typically much lower (hypoxic) than 
these standard culture conditions. Therefore, oxygen tension represents an important environmental 
factor that may affect how MSCs perform in vivo. However, the impact of hypoxic conditions on distinct 
mesenchymal stem cell characteristics, such as the proteasomal status, still remains unclear. 
We applied our method to analyze the 20S proteasome status after 10 days of ADSCs expansion under 
three different oxygenation concentrations: 1%, 5%, and 20%. Interestingly, proteasome abundance, 
proteolytic activity and composition were all affected by dioxygen levels (Figure 5 A-C). Indeed, when 
comparing the effect of ADSC expansion in hypoxic or normoxic conditions (1% vs. 20% O2 levels), we 
detected a significant increase in total 20S proteasome abundance alongside a nearly 2-fold significant 
upregulation of the three immunoproteasome catalytic subunits (Figure 5A&C). Both changes probably 
account for the higher 20S proteasome chymotrypsin-like activity measured following culture in 
normoxic conditions (Figure 5B). Indeed, structural differences in active sites account for the higher 
chymotrypsin-like activity of the β5i subunit of the immunoproteasome compared to its β5 standard 
counterpart (5, 45). Moreover, the relative abundance of 20S proteasome-associated PA28αβ activator 
is decreased in hypoxia compared to normoxia (p = 0.02) while the O2 level had no significant impact 
on the level of association of the other 20S CP regulators (Supplementary Figure 10B). This last 
observation further supports the increase measured in immunoproteasome subtype in normoxic 












compared to hypoxic conditions as PA28αβ is known to preferentially associate with the 20S 
immunoproteasome variant in cellulo (34).  
Overall, in the absence of IFNJ in the culture medium, the major proteasome subtype observed in 
ADSCs was the standard proteasome, which represented 60 to 80% of the total proteasome pool, 
depending on patient and O2 level (Sup Figure 9A). Given the massive induction of immunoproteasome 
upon exposure to the pro-inflammatory cytokine (Figure 4C) and the absence of immune cells in the 
ADSC culture medium, the inter-individual differences observed in immunoproteasome content might 
result from variability in the inflammatory context before surgery. Immunoproteasome subunits have 
been shown to be required for adipocyte differentiation (29). Accordingly, our data indicate that high 
levels of immunoproteasome correlate with high adipogenic potential at 20% O2, and the reverse 
under hypoxic conditions (Figure 5D). Strikingly, pharmacological inhibition of the immunoproteasome 
using the ONX0914 inhibitor (46) leads to a marked decrease in the capacity of ADSCs to differentiate 
into adipocytes, which confirms previous observations in the PSMB8 KO mice (29) using an orthogonal 
method. 
To get a broader picture of the effect of O2 levels on the proteome of ADSCs, a whole proteome analysis 
was performed on ADSCs grown under normoxic or in hypoxic conditions (1% of O2). Importantly, a 
new cohort of three patients was used to obtain this new biological material. Out of 3624 proteins 
identified and quantified, 67 proteins were found at increased levels in hypoxic conditions and 129 
were over-represented in normoxic conditions (Supplementary Figure 11 and revised Supplementary 
Data 7). All three immunocatalytic subunits were increased under normoxic conditions (fold increase 
of 1.6 to 1.9) although statistical significance was only reached for β1i and β2i (p-value = 0.05). As 
discussed above (supplementary Figure 7), this apparent discrepancy can easily be explained by the 
lower precision of label-free quantification results compared with SRM quantification data.  
Functional analysis based on GO Biological processes revealed the most significant pathway related to 
the proteins for which abundance was modified both under hypoxic and normoxic conditions to be the 












“oxidation-reduction” pathway (FDR = 1.2E-06 and 5.9E-03 for proteins up-regulated in hypoxic and in 
normoxic conditions, respectively). This result was to be expected following a change in O2 levels from 
20% to 1%. Other enriched GO biological pathways included “response to oxidative stress” (FDR = 4.2E-
02) in the proteins that were more abundant in normoxic conditions. This pathway is particularly 
interesting as the immunoproteasome has been associated with responses to oxidative stress (47–49). 
ADSCs were also shown to negatively regulate oxidative stress in vivo (50) and notably through Nrf2 
which is one of the main transcription factors involved in controlling oxidative stress. In our whole-
proteome analysis, we observed that NQO1 (two-fold increase, p-value = 0.02), one of the best-known 
targets of Nrf2 (51), was increased under normoxic compared to hypoxic conditions. Reactive oxygen 
species seem to play an important role in adipocyte differentiation (52–54). A function of the 
immunoproteasome related to ADSC differentiation could be the clearance of proteins having 
undergone oxidative damage, when this type of damage accumulates it could be toxic for the cell. 
Significantly, 25 of the proteins for which overall abundance differences were detected are functionally 
related to the “cell differentiation” GO Biological Process (FDR = 1.4E-02 for proteins over-represented 
in cells grown under hypoxic conditions). Among these, 16 were increased in the hypoxic cells whereas 
9 were decreased. These proteins are listed in Supplementary Data 7 (4th sheet). Given the importance 
of the immunoproteasome in regulating ADSC differentiation when stimulated with dexamethasone, 
and because our results clearly demonstrate that the immunoproteasome is increased under normoxic 
compared to hypoxic conditions, it is tempting to speculate that some of these deregulated proteins 
might be direct or indirect targets of the immunoproteasome. In particular, Transforming growth 
factor-beta-induced protein ig-h3(TGFBI/BGH3) and Plasminogen activator inhibitor 1 (PAI1) were 
both increased in our hypoxic cells (4.1- and 2.9-fold increase, respectively, with p-values of 8.5E-4 and 
0.03, respectively), and these proteins are known to be target genes of TGFβ1, a pathway required for 
hypoxia-mediated inhibition of adipocyte differentiation (55). Of course, further experiments will be 
necessary to confirm that these proteins are downstream players of the immunoproteasome affecting 
the adipogenic potential of ADSCs. 












In conclusion, after as few as 10 days of ADSCs expansion under different dioxygen levels, the method 
developed could detect mild but still significant changes in 20S proteasome status, and in particular 
variations in the level of 20S immunoproteasome. This change in proteasome composition might be 
causal for the observed O2-induced variations in differentiation potential of ADSCs even though further 
investigation will be required to determine the precise mechanisms.  
 
Discussion 
This study aimed to develop an assay to determine subunit absolute quantity and stoichiometry within 
a highly heterogeneous macromolecular protein complex, the 20S proteasome. To achieve this goal, a 
robust, accurate and sensitive absolute quantification method with multiplexing ability had to be 
developed to allow the absolute quantification of the 19 different subunits of the 20S proteasome in 
a single assay. 
Absolute quantitation based on IDMS using the SRM scanning mode suits the requirements for 
multiplex detection and is also recognized for its specificity, sensitivity, and accuracy (16, 17). Because 
many proteasome subunits had to be analyzed, we first used the most straightforward IDMS 
proteomics strategy, the AQUA (18) method, which involves spiking various isotope-labeled synthetic 
peptides into samples as internal standards. Although mainly used for the absolute quantification of 
monomeric proteins, the AQUA method has also been successfully applied to assess the sub-
stoichiometric incorporation of the Rpn13 ubiquitin receptor within the 26S proteasome (56). Our 
AQUA peptide sequences were carefully chosen to meet the requirements for IDMS analysis of 
proteins (16) and, when tested in simple or more complex biological matrices, they provided good 
linearity in signal response, low variability, and adequate sensitivity. These analytical performances 
explain why the AQUA technology was so rapidly adopted for the LC-SRM validation of protein 
biomarkers in various biological matrices (16, 17) . However, we noted a defect in trueness that was 
easily detected in our system because non-catalytic proteasome subunits are expected to be present 












at equimolar stoichiometry. Responses were observed to be highly dependent on peptide sequences, 
probably because of incomplete enzymatic digestion of the protein of origin; other reasons for the 
discrepancy observed could be incomplete peptide solubilization, peptide instability, or artefactual 
chemical modifications. Thus, isotope-labeled peptides could not be used to accurately assess 
proteasome subtype stoichiometry unless laborious optimizations were undertaken (19). Several IDMS 
methods based on the use of isotope-labeled protein standards like PSAQ (21), absolute SILAC (22), 
PrEST (23), or TAQSI (25) were developed to overcome the issues of the AQUA methodology. To the 
best of our knowledge, none of these has yet been applied to determine protein complex 
stoichiometry. To achieve this goal on highly heterogeneous 20S proteasome complex, we optimized 
a workflow relying on SILAC-based absolute quantification. A reference mixture containing equimolar 
concentrations of both isotope-labeled and purified 20S standard- and immuno-proteasome subtypes 
was produced, qualitatively and quantitatively assessed, and spiked into protein lysates extracted from 
cell cultures or tissues. After protein digestion, the SRM method was optimized for carefully chosen 
proteotypic peptides. In this approach, use of a whole isotope-labeled protein as internal standard 
represents a clear advantage over the PrEST approach (23) because all proteotypic peptides can 
theoretically be used for quantification. This method was validated by comparison with the reference 
ELISA method for total 20S proteasome absolute quantification in a broad range of biological samples.  
Although 20S and 26S proteasome complexes can be routinely quantified using different ELISA assays 
(6, 10–14, 33), this technique lacks the multiplexing capacity to assess the complete diversity of 
proteasome subtypes because up to 19 different protein chains can be incorporated into the 20S 
proteasome macromolecular assembly (Figure 1A). Moreover, to our knowledge, the precise 
stoichiometries of tissue-specific β5t- and D4s-containing 20S proteasome subtypes have never yet 
been determined. Using our optimized assay, for the first time, we accurately quantified the 
stoichiometry of the tissue-specific thymoproteasome and spermatoproteasome; their low levels in 
thymus and testes tissues (20% and 12% of the total 20S proteasome pool, respectively) support 












findings in previous reports showing that β5t and α4s are detected in a subpopulation of cells in these 
two organs (4, 58). 
Then, we demonstrated that our method could also precisely monitor changes in 20S proteasome β 
catalytic subunit composition following IFNJ-activation of HeLa cells. We took advantage of the known 
stoichiometry of β catalytic subunits in the 20S proteasome to assess the trueness of the method, 
which exceeded 96%. In comparison, the TOP3 label-free quantification approach barely achieves 78% 
accuracy after discarding outliers arising from unrepresentative peptides. Converting peptide 
abundance into protein concentration requires careful selection of peptide sequences and 
optimization of SRM transitions (19) or, alternatively, the removal of incoherent peptides from global 
MS1-based quantification datasets, for instance using covariation of peptide abundances (59). Thus, 
even if label-free MS1-based quantification methods can be used to obtain a rough estimate of protein 
complex stoichiometry, as previously reported (60–62), these approaches are most appropriate for the 
high-throughput determination of changes in the relative abundances of protein complex subunits (34, 
35) or estimation of protein copy-number without requiring spike-in standards (63).   
MSCs obtained from bone marrow (BM-MSCs) or AT (ADSCs) are promising tools for cell therapy in 
regenerative medicine, to treat severe inflammatory and autoimmune diseases, or to prevent 
transplant rejection (64). Cells must be expanded ex vivo to obtain sufficient numbers for use in 
therapy. Thus, culture conditions must be carefully controlled both for safety issues and to optimize 
therapeutic effectiveness. Using our method, we showed that pre-stimulation of ADSCs with IFNJ and 
increasing O2 levels both affect the status of the 20S proteasome during ex vivo expansion of primary 
ADSCs. In both cases, changes in proteasome composition were observed, in particular an increase in 
immunoproteasome stoichiometry. These results emphasize the high plasticity of the 20S proteasome 
when exposed to external stimuli, but also the multiple biological roles played by the 
immunoproteasome subtype. IFNJ is known to induce the immunoproteasome through the formation 
of new proteasome particles incorporating immunocatalytic subunits in place of the standard ones. 












Pre-stimulation of both BM-MSCs and ADSCs with pro-inflammatory cytokines, in particular IFNJ, has 
been shown to increase their immunosuppressive properties (43, 64, 65), by increasing release of 
several soluble immunosuppressive factors, in particular kynurenine, a product of indoleamine 2,3-
dioxygenase (IDO) activity (65). Moreover, both BM-MSCs and ADSCs are antigen presenting cells (64) 
and, when exposed to IFNJ, they up-regulate expression of HLA class I molecules on their surface. This 
response protects them from NK-mediated lysis (43, 66), and promotes their immunomodulatory 
effects. Strikingly, both mechanisms linked to the immunosuppressive properties of MSCs are affected 
by proteasome status. Indeed, a shift from standard to immunoproteasome considerably increases the 
production of MHC class I-binding peptides in vivo (67) and IDO is known to be a proteasome substrate 
(68). Proteasome-mediated degradation of IDO was recently reported to explain the reduction in 
immunosuppressive potential observed in clinical-grade expanded MSCs which had reached replicative 
senescence (42). Mechanistically, IFNJ is known to increase IDO protein via transcriptional activation 
(69) but it is also responsible for a strong induction of the immunoproteasome-PA28αβ complex, a 
proteolytic system functioning in the absence of ubiquitination (67). As IDO is degraded through the 
ubiquitination-dependent SOC3-proteasome pathway (68), the increase in ubiquitin-independent 
degradation triggered by IFNJ might constitute a mechanism further promoting IDO stabilization in this 
physiological context. 
In addition to its major role in antigen processing, the immunoproteasome seems to degrade oxidized 
proteins more efficiently than the standard 20S CP (70, 71). De novo synthesis of 20S proteasome and 
in particular of immunoproteasome is crucially important for maintaining efficient proteostasis in 
oxidative stress conditions (49). The evidence provided here of low total proteasome content and an 
absence of immunoproteasome in brain probably accounts for the previously reported higher 
sensitivity of brain tissues to oxidative stress (72). Activation of the immunoproteasome and 
autophagy occur during the early stages of ESC differentiation, to allow degradation of damaged 
proteins and avoid their transmission to differentiated cells (27). Moreover, recent findings indicate 
that the immunoproteasome is required for differentiation of adipocytes (29) and skeletal muscle (28). 












In line with this requirement, our results demonstrate that ADSCs grown under hypoxic conditions, 
had a lower immunoproteasome content and exhibited a lower differentiation potential than their 
counterparts grown under 20% O2. In addition, our results suggest that immunoproteasome activity is 
causal for the change in adipogenic potential in normoxic conditions. Thus, the significant increase 
observed in all three immunocatalytic subunits and in overall proteasome activity in normoxia-cultured 
primary ADSCs compared to the cells cultured in hypoxic environments could reflect modulation of 
their therapeutic capacities. Importantly, ADSCs are adult pluripotent stromal stem cells isolated from 
white AT where O2 levels are below 5% but they are routinely expanded ex vivo under 20% O2. 
Manufacturing practices for ASC expansion must therefore be carefully optimized and controlled to 
maintain their therapeutic capacity. The results from the approach developed here applied to primary 
ADSCs grown in conditions close to real clinical production clearly demonstrate that IFNJ and dioxygen 
levels could be key parameters in this process. 
To conclude, the method presented here allows robust and rapid determination of the complete 
status, i.e., absolute quantity and stoichiometry, of a highly heterogeneous macromolecular protein 
complex, the 20S proteasome, in various human tissues and cells. When applied to primary ADSCs 
expanded in different culture conditions, our results highlighted a high plasticity in proteasome 
composition and abundance which might be related to modulation of the ADSCs’ immunosuppressive 
and differentiation properties. The method developed thus constitutes a sound approach to 
complement immunophenotyping or other methods to monitor protein markers (73) for the 
optimization and control of manufacturing processes for ADSCs expansion. Knowledge of proteasome 
composition is also of major interest for therapeutic purposes. Indeed, upregulation or dysregulation 
of immunoproteasome catalytic subunits have been observed in several human diseases and 
disorders, such as inflammatory and autoimmune diseases, cancer, diseases of the central nervous 
system, and aging (74). For instance, mutations reported in immunocatalytic subunits and the resulting 
defects in 20S immunoproteasome assembly and activity observed in PRAAS (Proteasome-Associated 
Autoinflammatory Syndrome) patients could be monitored using our method (reviewed in (75)).  Our 












assay could also be of great interest when seeking to assess patients before instigating immuno-
therapy as the efficacy of tumor antigen processing and presentation is closely linked to levels of 20S 
immune-type proteasomes in antigen presenting cells (75). Detection of increased concentrations of 
20S proteasomes or changes in subtype profiles could also be monitored in extracellular body fluids to 
diagnose and/or as a prognostic marker of various diseases (76). In this context, a more specific 
targeting of the different heterogeneous forms of the proteasome will lead, in the long run, to more 
specific treatments generating fewer side effects and less chemoresistance than caused by broad-
spectrum proteasome inhibitors (77). However, to design such targeted therapies, tools to precisely 
determine patients’ proteasome status, like the one presented here, will need to be developed. 
More generally, the developed strategy could be extended to assess the absolute level, dynamic, and 
heterogeneous nature of many other biologically-relevant macromolecular systems such as the human 
spliceosomal hprp19/CDC5L complex (19, 61), the nuclear pore complex (78), core ribosomal proteins 
(62), or even host-pathogens interactions (79). These adaptations would be more accurate than the 
peptide-based mass spectrometry methods currently used (61). The sole requirement for this 
adaptation is that it must be possible to ectopically produce and purify each individual subunit in 
carefully-controlled absolute quantities with heavy-isotope incorporation.  
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Figure 1: workflow for determination of total 20S proteasome absolute quantity and stoichiometry 
by LC-SRM 
A- Schematic representation of the six main 20S proteasome subtypes with different sets of subunits. 
The sP20S is the most abundant 20S subtypes in most cell types. The 20S proteasome subtypes 
containing at least one immunocatalytic subunit are predominantly observed in immune cells but can 
also be induced in response to inflammatory cytokines. Other 20S proteasome subtypes are tissue-
specific, like the thymoproteasome (β5t P20S) and the D4s proteasome (D4s P20S) which have been 
observed in the thymus and in reproductive cells like testes, respectively.  
B- Determination of total 20S proteasome quantity and 20S subtypes stoichiometry in Human cell 
lysates or tissues using SRM. Endogeneous proteasomes contained in biological samples were digested 
with trypsin. The SRM approach was designed to quantify in a multiplexed manner a set of proteotypic 
peptides corresponding to D subunits, as well as β catalytic and non-catalytic subunits. Isotope-labelled 
standard and immunoproteasome complexes were used as internal standards in the final method. 
They were spiked in the biological sample at equimolar quantities before the tryptic digestion. 
Alternatively, heavy « AQUA » peptides were added to the endogeneous peptides lysate after tryptic 
digestion. At least three endogeneous peptides, and three transitions per peptide were analyzed. 
Thanks to internal normalization with the isotopically-labeled peptides transitions, the absolute 
quantity of selected D and β non-catalytic subunits as well as of β catalytic subunits were obtained and 
used to compute the absolute quantities of total 20S proteasome and to assess the stoichiometries of 
the six main 20S proteasome subtypes in biological samples. Details are provided in the Experimental 
Procedures section and in Experimental section.  
 
Figure 2: Final validation of the LC-SRM method to determine absolute quantity of total 20S 
proteasome and to precisely and accurately monitor the dynamics of 20S subtypes stoichiometries 












A- Correlation curve between the 20S proteasome concentration measured by the ELISA reference 
method and the one determined by LC-SRM in a panel of eight human cell lines (HEK 293T, HCT116, 
RKO, U937, HeLa S3, NB4, KG1a, and MRC5). The LC-SRM method was based on the isotopic dilution 
of equimolar amounts of in-house isotopically-labeled sP20S and iP20S (R(13C6) and K(13C6)) in each cell 
line protein lysate. One peptide sequence (and three transitions for the light and the heavy surrogate) 
and three peptide sequences were analyzed for non-catalytic subunit (α1-7; β3,4,6,7) and catalytic 
subunits (β1,2,5,1i, 2i, 5i), respectively (see Supplementary Data 3 for more details on peptides and 
transitions). An equivalent of 2.5 μg total proteins containing the sP20S and iP20S heavy internal 
standard mix were injected on column and analyzed by SRM, as detailed in the Experimental 
Procedures. Three biological replicates (and three technical replicates) were analyzed to obtain 
statistics. The total proteasome concentrations measured in the initial protein lysates are presented. 
B- Dynamics of 20S subtypes stoichiometries upon IFNJ stimulation of HeLa cells. The absolute 
quantities of each of the six catalytic subunits measured by the LC-SRM method were computed to 
calculate the stoichiometries of 20S proteasome subtypes as detailed in Experimental Procedures. 
HeLa cells were stimulated for 0, 24, 72, or 96 h with IFNJ and the SRM method used to quantify 
proteasome subunits in each total cell lysate obtained at each time point of cytokine stimulation. 
Peptides sequences, transitions and applied voltages are detailed in Supplementary Data 3. Three 
biological replicates were analyzed to obtain statistics. The sum of the stoichiometries of the four 20S 
proteasome subtypes is very close to the expected value of 100 (obtained from independent 
measurement of total 20S proteasome absolute quantity). 
C- Method variability (CV %) and accuracy (%) calculated with data obtained from IFNJ-stimulated HeLa 
cells. Accuracy was calculated from comparison of total 20S proteasome quantity obtained from non-
catalytic subunits (reference values) and from β1/β1i, β2/β2i, and β5/β5i couples of catalytic subunits 
(experimental values) (n = 36). Accuracy were computed as follow: accuracy = (experimental value – 
reference value) / reference value * 100. Method variability: Coefficients of variation on all 












independent measurements (n = 24). Details on stoichiometry determination of 20S proteasome 
subtypes are provided in Experimental Procedures. 
 
Figure 3: The method is able to precisely and accurately monitor 20S proteasome absolute quantities 
and subtypes stoichiometries in a panel of human tissues 
A: Proteasome 20S absolute quantity (% w/w total proteins) measured by the LC-SRM method and 20S 
Proteasome chymotrypsin-like activity measured by degradation of LLVY-AMC peptide, in a panel of 
11 human tissues. 
B: Label-free relative quantification of tissue-specific 20S proteasome subunits by label-free LC MS/MS 
reveals the tissue-specificity of α4s and β5t subunits but not the one of immunocatalytic subunits. 
Relative abundances of each subunits across the tissues are represented. The highest abundance is 
arbitrarily set to 1. 
C:  Stoichiometries of the six proteasome 20S subtypes in different Human tissue determined by the 
LC-SRM method. Details on stoichiometry determination of 20S proteasome subtypes are provided in 
Experimental Procedures. 
D: Biplot Principle Component Analysis of 11 human tissue samples (3 replicates per tissue) based on 
20S proteasome catalytic subunits composition. The dashed circles represent the main clusters 
observed depending on content on standard (β1, β2, β5) or immuno (β1i, β2i, β5i) subunits. 
 
Figure 4: Proteasome status is affected by priming ADSCs with IFNJ during their ex-vivo expansion 
A: Workflow for the determination of the effect of priming of ADSCs with interferon-J on their 20S 
proteasome status, using the LC-SRM method. Primary cells obtained from two patients were used for 
the study. 












B: Proteasome 20S absolute quantity (% w/w total proteins) measured by the developed LC-SRM 
method in ADSCs obtained from patients (n = 2 biological replicates – 3 technical replicates). 
C: Fold change in the six catalytic subunits of the 20S proteasome during IFNJ stimulation. ADSCs were 
cultivated in the presence of the cytokine (100 ng/ml). Absolute quantities of the catalytic subunits 
were determined by the developed LC-SRM approach and fold changes are calculated relative to time 
0h (n=2 biological replicates – 3 technical replicates).  
D: Dynamics in the stoichiometries of 20S proteasome subtypes during the course of IFNJ stimulation 
of primary  ADSCs derived from patients (n = 2 biological replicates – 3 technical replicates). 
Calculations are detailed in Experimental Procedures. 
 
Figure 5: Expansion of ADSCs in different O2 levels affect 20S proteasome status and ADSCs’ capacity 
to differentiate 
A: Proteasome 20S absolute quantity (% w/w total proteins) measured by the LC-SRM method in five 
patients derived primary ADSCs cultivated at three different levels of O2 (1%, 5%, and 20%). 
B: Proteasome 20S chymotrypsin-like activity measured by the in vitro degradation of the LLVY-AMC 
peptide by proteasome in ADSCs lysates after cultivation in three different levels of O2 (1%, 5%, and 
20%) (n = 5 patients – 3 technical replicates). 
C: Relative content of standard and immuno catalytic 20S proteasome subunits measured by the 
method in five patients derived primary ADSCs cultivated at three different levels of O2 (1%, 5%, and 
20%).  
D: Differentiation potential of human ADSCs from different patients under different levels of O2 (1%, 
5%, and 20%). The immunoproteasome inhibitor ONX-0914 alters the differentiation capacity of ADSCs 
at 5% and 20% O2 concentrations. Adipogenic differentiation is indicated by Oil red O staining. 
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